Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas
Authors:
- James A. SimonJSJames A. Simon
- Ayman Al-HendyAAAyman Al-Hendy
- David F. ArcherDADavid F. Archer
- Kurt T. Md BarnhartKBKurt T. Md Barnhart
- Linda D. BradleyLBLinda D. Bradley
- Bruce R. CarrBCBruce R. Carr
- Thomas DayspringTDThomas Dayspring
- Eve C. FeinbergEFEve C. Feinberg
- Veronica GillispieVGVeronica Gillispie
- Sandra HurtadoSHSandra Hurtado
- JinHee KimJKJinHee Kim
- Ran LiuRLRan Liu
Open Access
- 7 May 2020
- journal article
- conference paper
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 135 (6) , 1313-1326
Abstract
OBJECTIVE: To investigate the safety and efficacy of elagolix, an oral gonadotropin-releasing hormone antagonist, with hormonal add-back therapy for up to 12 months in women with heavy menstrual bleeding associated with uterine leiomyomas. METHODS: Elaris UF-EXTEND was a phase 3 extension study that evaluated an additional 6 months (up to 12 months total) of elagolix 300 mg twice daily with hormonal add-back therapy (estradiol 1 mg and norethindrone acetate 0.5 mg once daily) in women who completed an initial 6 months of the same treatment in one of two preceding phase 3 studies. The primary endpoint was the percentage of women with both less than 80 mL menstrual blood loss during final month and a 50% or greater reduction in menstrual blood loss from baseline to final month. Safety evaluations included adverse events and bone mineral density changes. The planned sample size of UF-EXTEND was based on estimated rollover and discontinuation rates in the two preceding studies. RESULTS: From September 2016 to March 2019, 433 women were enrolled in UF-EXTEND. Of these women, 218 received up to 12 months of elagolix with add-back therapy; the mean±SD age of this group was 42.4±5.4 years and 67.3% were black. The percentage of women who met the primary endpoint in this elagolix with add-back group was 87.9% (95% CI [83.4–92.3]). The most frequently reported adverse events with up to 12 months of elagolix plus add-back therapy were hot flush (6.9%), night sweats (3.2%), headache (5.5%), and nausea (4.1%). Mean percent decreases in bone mineral density from baseline to extension month 6 were significantly less with elagolix plus add-back therapy than with elagolix alone {between-group difference in lumbar spine: −3.3 (95% CI [−4.1 to −2.5])}. CONCLUSION: Up to 12 months of elagolix with add-back therapy provided sustained reduction in menstrual blood loss in women with uterine leiomyomas, with the addition of add-back therapy attenuating the hypoestrogenic effects of elagolix alone. No new or unexpected safety concerns were associated with an additional 6 months of elagolix with addback therapy. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02925494. FUNDING SOURCE: AbbVie Inc funded this study.Keywords
This publication has 24 references indexed in Scilit:
- Beyond the physical: A qualitative assessment of the burden of symptomatic uterine fibroids on women's emotional and psychosocial healthJournal of Psychosomatic Research, 2015
- Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterolJournal of Lipid Research, 2015
- Iron-dependent erythropoiesis in women with excessive menstrual blood losses and women with normal mensesAnnals of Hematology, 2013
- Endogenous Estrogens Lower Plasma PCSK9 and LDL Cholesterol But Not Lp(a) or Bile Acid Synthesis in WomenArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- The estimated annual cost of uterine leiomyomata in the United StatesAmerican Journal of Obstetrics and Gynecology, 2012
- Validation of a rapid alkaline hematin technique to measure menstrual blood loss on feminine towels containing superabsorbent polymersFertility and Sterility, 2011
- Validating a pencil-and-paper measure of perimenopausal menstrual blood lossWomen's Health Issues, 2004
- Self-reported heavy bleeding associated with uterine leiomyomataObstetrics & Gynecology, 2003
- Uterine fibroidsThe Lancet, 2001
- Assessment of menstrual blood loss using a pictorial chartBJOG: An International Journal of Obstetrics & Gynaecology, 1990